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Cannabinoids have long been a part of human culture and medicine, and more recently have 
been rediscovered for their potential use in the management of rheumatic disease pain. The 
objective of this review was to evaluate the known clinical effectiveness of cannabidiol 
treatment for rheumatic disease related pain. The legality and current regulation of these 
products was also reviewed to establish the current status of federal and state rules regarding 
their clinical use. Basic definitions of the terms used to differentiate cannabidiol from other 
cannabinoid products was also outlined. A systematic literature search was then conducted to 
explore the current pool of evidence pertaining to the defined phenomena of interest and 
clinical question. Five electronic databases were selected to generate a comprehensive 
selection of evidence. Twenty-one articles were identified and evaluated for appropriateness 
of fit within the defined inclusion and exclusion criteria. Articles relating to the use of 
cannabidiol in any form for the treatment of rheumatic disease pain in adults were included. 
Research articles pertaining to non-rheumatic diseases, psychiatry, children, adolescents, 
medical cannabis, or tetrahydrocannabinol alone were excluded. A total of nine studies met 
inclusion criteria. Findings from those studies concluded that current evidence is lacking in 
quality, quantity, and in key factors regarding the efficacy, tolerability, and safety of 
cannabidiol for rheumatic disease relief pain. Furthermore, due to the lack of evidence 
evaluating cannabidiol use for rheumatic disease pain, additional clinical studies are needed 
to evaluate their usefulness. Best practice and research recommendations were also proposed 
based of the systematic review and current body of evidence. 




Exploring the Effectiveness of Cannabidiol Use in Rheumatic Disease Pain: 
A Systematic Review 
Cannabinoids have been a part of human culture for the past millennia and used for 
various medicinal purposes (Sarzi-Puttini et al., 2019). Presently, the use of cannabinoids for 
chronic pain relief is rapidly increasing as the unrestricted availability of these products steadily 
surges. It is a frequent occurrence to find products containing cannabinoids sold online or at any 
local convenience or grocery store claiming to aid the management of many conditions including 
arthritis pain relief. Additionally, the marketing of the cannabidiol or CBD for arthritis pain relief 
has also exponentially increased, leading to the dissemination of scientifically unsubstantiated 
claims. Within the scientific community, many uncertainties and controversies remain regarding 
the role of cannabinoids for the management of rheumatic pain (Perrot & Trouvin, 2019). This is 
further compounded by the confusion between different forms of cannabis plants and products 
such as herbal cannabis, medical cannabis, and cannabinoids (Perrot & Trouvin, 2019). 
Therefore, it is important to differentiate these products and look beyond the anecdotal claims as 
these ancient drugs are now being rediscovered and reconsidered as potential modern analgesic 
therapies by patients (Perrot & Trouvin, 2019). This review aims to evaluate the current body of 
clinical evidence available to support the clinical use of CBD oil for rheumatic disease pain relief 
in order to suggest clinical practice recommendations. 
Background 
 Cannabinoids have long been used for recreational, medicinal, and even ceremonial 
purposes (Sarzi-Puttini et al., 2019). Early uses of cannabinoids for medicinal purposes in 
conditions such as rheumatic pain, constipation, and even malaria, date back to 28th century BC 
(Sarzi-Puttini et al., 2019). More recently cannabinoid products have been used around the world 
for its therapeutic properties in chronic pain relief, epilepsy, and opioid addiction. Additionally, 
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social or recreational use of cannabis products is growing as many states are legalizing their use 
despite the paucity of evidence regarding their safety and efficacy (Sarzi-Puttini et al., 2019).  
 Cannabinoids are natural compounds derived from the cannabis plant family. There are 
more than 100 known cannabinoids; the most common cannabinoids used are 
tetrahydrocannabinol (THC) and CBD. Derived from the cannabis sativa plant, CBD has been 
used for centuries in various medicinal preparations for the treatment of chronic pain, a cardinal 
symptom of many rheumatological diseases (Sarzi-Puttini et al., 2019). Rheumatic diseases, such 
as osteoarthritis, represent a group of painful conditions where conventional analgesics show 
poor efficacy and inadequate long-term control of pain relief (Perrot & Trouvin, 2019). Thus, 
CBD oil has grown to be a popular option as a potential new therapeutic alternative for 
rheumatic pain (Perrot & Trouvin, 2019). The rationale for its use in arthritis is based not only on 
its analgesic effects, but also on its anti-inflammatory effects and immunomodulatory activity 
(Perrot & Trouvin, 2019). Due to its lack of psychoactive properties, CBD oil is a seemingly safe 
choice for patients who are seeking alternatives for pain relief (Sarzi-Puttini et al., 2019). 
Nevertheless, centuries old use, the absence of psychotropic properties, and lack of other 
effective therapies is not sufficient evidence to prove that CBD oil is a useful or safe treatment 
for rheumatic pain (Sarzi-Puttini et al., 2019). 
 The legality, safety, and efficacy of CBD is often called into question as many healthcare 
providers are uncertain of the existing supportive evidence and current regulation of CBD oil. 
Skepticism of the effectiveness of CBD oil, stemming from the lack of current evidence, has left 
many health care professionals calling for more validation to be done regarding its usefulness in 
clinical practice (Sarzi-Puttini et al., 2019). Likewise, validating patient reported treatments that 
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improve rheumatic disease pain necessitates further clinical studies of CBD oil to determine if it 
plays any clinical role in the management of these disorders.  
 Additionally, as the cannabinoid industry explodes into the mainstream consumer market, 
associated terminology and understanding of specific terms is often misunderstood and misused. 
Commonly used terms include cannabinoids, cannabidiol, cannabis, hemp, marijuana, hemp seed 
oil, CBD oil, medical marijuana, THC, and cannabis oil. Often, many of these terms are used 
interchangeably, leading to confusion for patients and providers alike. Lastly, many products 
have been found to contain a mixture of cannabinoids with mislabeled concentrations, creating 
uncertainty surrounding which cannabinoid may be providing relief or found to have harmful 
side effects. 
Definitions 
 Familiarity with commonly used terminology of CBD products is necessary to 
understand the clinical phenomenon of interest as their various terms used. Knowledge of the 
definitions of these terms is important to differentiating CBD from other cannabinoid products. 
The Endocannabinoid System  
The endocannabinoid system or ECS, is a newly discovered system within the human 
body. It acts as a homeostatic regulator of functions within the brain, cardiovascular system, 
digestive track, liver, and even bone (Russo, 2016). This system is comprised of a triad of 
cannabinoid receptors including CB1, CB2, TRPV1, endogenous cannabinoids such as 




 Cannabinoids are compounds derived from the cannabis plant family. These naturally 
occurring chemical compounds are the active ingredients found in cannabinoid products 
(VanDolah et al., 2019). These compounds include THC and CBD. 
Tetrahydrocannabinol  
THC is the primary psychoactive cannabinoid found in the Cannabis sativa L. plant. THC 
is a phytocannabinoid or plant-derived cannabinoid that is a CB1 receptor agonist, known for 
producing intoxicating CNS effects (VanDolah et al., 2019).   
Cannabidiol  
This is a non-intoxicating cannabinoid extracted from the flowers of the female Cannabis 
sativa L. plant and is used for its therapeutic properties in pain relief (VanDolah et al., 2019). 
CBD oil has become especially popular as an over the counter medication because of its low 
THC levels resulting in medical benefits such as pain relief without the euphoric sensations 
associated with marijuana (VanDolah et al., 2019). It binds to the TRPV1 receptor and does not 
have any intoxicating effects. 
Hemp 
 Hemp is a species of the Cannabis sativa L. plant that contains less than 0.3% THC. 
Often its fibers are used for clothing and its oil is used in cosmetic products. It does not contain 
enough THC to have psychoactive properties, yet it does contain CBD. As of January 1, 2020, 
products containing CBD derived from hemp can be legally sold under Minnesota state law 
(Minnesota Department of Agriculture, 2020). 
Hemp Seed Oil 
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This is created from the seeds of the hemp plant and does not contain any cannabinoids. 
It is often used as a nutritional supplement or in clothing and fibers. It also contains omega-6 and 
omega-3 fatty acids and other antioxidants (VanDolah et al., 2019).  
Cannabis Oil  
Cannabis oil is derived from the marijuana plant which is also of the same plant species 
Cannabis sativa L. Its THC levels are directly related to genetic differences in cannabis sativa 
plants and specific growing techniques. Cannabis oil contains high levels of THC and is only 
legal to produce by medical cannabis manufacturers licensed by the Minnesota Department of 
Health (Minnesota Department of Agriculture, 2020).  
Clinical Phenomenon of Interest 
Cannabidiol, or CBD, seems to be available almost everywhere. It is marketed as a 
product to help with pain, anxiety, and even seizures. There is significant public interest in 
cannabis derived products despite many unanswered questions regarding the safety, efficacy, and 
quality of products containing CBD. Additionally, the U.S Food and Drug Administration (FDA) 
only recognizes the use of CBD products for two rare forms of epilepsy (U. S. Food and Drug 
Administration, 2019). Thus, an urgent need for analysis of the current body of evidence and its 
findings is crucial to evaluate the safety, efficacy, and potential for adverse effects of CBD oil. 
While some patients may feel that these products are safe, rigorous scientific studies 
demonstrating their effectiveness and safety are insufficient. Furthermore, providers are often 
asked by their patients if these products work and if there are any known benefits. Therefore, 
providers must be astutely aware of scientific evidence regarding the safety and efficacy of CBD 




Presently, CBD oil products are being sold as dietary supplements claiming to relieve 
arthritis pain yet have not been subject to FDA evaluation or been proven to have any therapeutic 
benefit. There is also limited research regarding the appropriate dosage of CBD oil, any food or 
drug interactions, or dangerous side effects of CBD oil (FDA, 2019). The FDA has tested the 
chemical contents of cannabinoid products sold over the counter and again have found they did 
not contain the levels of CBD as indicated on the label (FDA, 2019). There are also reports of 
cannabinoid products containing unsafe levels of contaminants such as pesticides, heavy metals, 
and THC (FDA, 2019). Thus, the potential for patient harm is undeniable given the lack of 
research needed to identify the proper dosage, the inconsistent labeling of CBD oil sold over the 
counter, and unproven anecdotal claims associated with these products. The potential to delay 
seeking appropriate medical care is also greater for patients using alternative therapies for pain 
relief that are not evidenced to be safe and effective. 
Clinical Question 
The PICO format was utilized to focus the literature search and refine the topic of clinical 
interest.  In adults experiencing pain due to rheumatic disease (P), how does cannabidiol use (I) 
compared to no use of cannabidiol (C) influence pain relief?  
Clinical Significance for Advanced Practice 
Many health care providers are uncertain about the efficacy, legality, and safety of over 
the counter products containing CBD oil used for pain relief. It is imperative that health care 
providers have a clear understanding of these aspects and CBD oil’s efficacy in treating 
rheumatic disease pain as patients may seek their counsel on the use of these products. A clear 
understanding of the clinical research conducted on the chief ingredients found in CBD oil 
products is the first step to informing primary care providers about the safety and efficacy. It is 
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well known that there are only a small number of clinical research studies conducted and 
disseminated regarding CBD oil products, as most research focuses on THC and its primary 
target, CB1 receptors (VanDolah et al., 2019). Therefore, this lack of evidence significantly 
impacts the potential for advocacy of the use of these products.        
Legal and Regulatory Considerations 
 The sale of over the counter CBD oil products are currently widespread throughout the 
United States. With the passage of the 2014 Agricultural Act, the growth of hemp or Cannabis 
sativa L. with a THC content of no more than 0.3% was legalized for the purposes of research in 
the United States and was removed from the Controlled Substances Act (VanDolah et al., 2019). 
It remained illegal, however, to introduce any supplement or food containing CBD into interstate 
commerce (VanDolah et al., 2019). Thus, most products were therefore imported from Europe, 
processed, and redistributed within the United States to be sold with little regulation (VanDolah 
et al., 2019). This led to widespread distribution of unregulated and mislabeled products 
commonly seen sold in many retail stores.  
 As of January 1st, 2020, the sale of over-the-counter hemp products containing CBD oil 
containing less than 0.3% THC can be legally sold under Minnesota law (Minnesota Board of 
Nursing, 2019). This new regulatory step also aims to reduce mislabeling as labeling conditions 
are clearly outlined and required for CBD oil products. The new labeling requirements must now 
include an accurate statement of ingredient amounts, a statement of the amount or percentage of 
cannabinoids found in each individual dose consumed, and a statement stating that the product 
does not claim to diagnose, treat, cure, or prevent any disease (Minnesota Board of Nursing, 
2019). The label must also state it has not been evaluated or approved by the FDA unless the 
product has been so approved (Minnesota Board of Nursing, 2019). 
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Safety and Adverse Effects 
 Of the few studies conducted examining CBD oil safety, a range of CBD oil doses from 
300 milligrams per day for 6 months to 1200 - 1500 milligrams per day for 4 months were used 
safely (VanDolah et al., 2019). However, studies with larger numbers of participants have found 
associated side effects with the use of CBD oil including somnolence, decreased appetite, 
diarrhea, and elevated liver function tests (VanDolah et al., 2019). Furthermore, some drug to 
drug interactions have been found as a result of the metabolism of CBD oil by the cytochrome 
P450 enzyme system including warfarin and various epilepsy medications (VanDolah et al., 
2019). Lastly, inconsistent branding of the ingredients within these products has included over 
labeling CBD content and under labeled THC (VanDolah et al., 2019). As a result, severe 
adverse reactions have led to two hospitalizations due to ingestion of these products (VanDolah 
et al., 2019).   
Methods 
A systematic literature search was conducted between the dates of 10/11/19 through 
10/25/19 to explore the current evidence pertaining to the defined clinical question. Five 
electronic databases were selected to generate a comprehensive selection of evidence. Articles 
were then evaluated for appropriateness of fit within the defined inclusion and exclusion criteria.     
Search Strategies 
To focus on the outlined clinical question, a broad range of applicable key words were 
selected and applied when searching all five databases. Boolean operators were also utilized to 
combine search terms and broaden the results. Key words were matched within all article text. 
This strategy was used to retrieve all studies examined within this review.     
Data Abstraction Process 
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Databases searched included CINAHL, CENTRAL, ProQuest, PubMed, and PsycINFO. 
Detailed database information, general search terms, specific dates, and search restrictions are 
included in Table 1 of the attached appendix. Studies were found using search terms including 
“CBD oil,” “cannabidiol,” “pain,” “pain relief,” “rheumatic disease,” ” inflammation,” “anti-
inflammatory,” “treatment efficacy,” “arthritis,” “analgesic,” and “join pain.” Search limits 
applied to database searches consist of only peer reviewed articles authored between 2006-2019, 
full text available, English language, Adults, Humans, Evidence-based healthcare, literature 
review, systematic review, abstract available, and scholarly journals. Article titles were then 
reviewed by the author when database searches concluded 10 hits or less. Titles were eliminated 
if they contained non-human subjects, children, adolescents, and non-rheumatic diseases. A 
complete list of unique matches included within this review are indicated in Table 2 in the 
appendix.     
Inclusion/Exclusion Criteria  
Articles relating to the use of CBD for the treatment of rheumatic disease pain in adults 
were included. Relevant studies that reviewed multiple types of cannabinoids individually, 
including CBD oil, were also incorporated in order to expand the amount of available literature. 
Research that discussed the history of cannabinoids was also incorporated. A total of 9 articles 
met inclusion criteria for this analysis. Refer to Table 3 for all reviewed articles with inclusion 
criteria rationale.   
Research articles pertaining to non-rheumatic diseases such as cancer, hepatic disease, 
epilepsy, children, or adolescents were excluded. Studies pertaining only to the use of medical 
cannabis or THC were excluded. Topics examining cannabinoid use in psychiatry were also 
excluded. Refer to Table 3 for all reviewed articles with exclusion criteria rationale.      
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Literature Review Process 
Fifty-three studies were identified using keywords and keyword combinations to search 
the five databases. Twenty-one studies were further reviewed for a fit with inclusion or exclusion 
criteria; 32 studies were duplicates. After evaluation of the final search results, nine studies fit 
the inclusion criteria and were included in this literature review. Those studies included one 
systematic review of randomized control trials, two randomized control trials, three reviews of 
mixed trials, one case study, and two articles of expert opinion. Detailed information regarding 
the purpose, sample size, level of evidence, variables, findings, and implications of all nine 
included studies are indicated in Table 4 in the appendix.  
Literature Review 
This literature review aims to identify the current body of evidence pertaining to the 
therapeutic use of cannabinoids, specifically CBD, for the treatment of rheumatic disease related 
pain. This research related to the effects of CBD on rheumatic disease pain will be synthesized. 
After meeting inclusion criteria, the nine studies were evaluated for strength of evidence and 
substantiation of therapeutic benefit with the use of CBD on rheumatic disease pain. 
Study Characteristics  
As described in the literature review process section, the highest level of evidence found 
was one level I systematic review while all other evidence discovered was a mixture of level II, 
III, VI, and VII. The nine studies included in this review are organized by level of evidence as 
follows: one systematic review, two randomized control trials (RCTs), three reviews of mixed 
trials, one case study, and two articles of expert opinion. The level I evidence identified by this 
systematic review was a systematic review of RCTs, that assessed the outcomes of cannabinoid 
use in patient with rheumatic disease. Level II studies consisted of two RCTs. Hunter et al. 
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(2018) evaluated the effects of CBD oil on pain and inflammation in osteoarthritis the knee and 
Blake et al. (2006) assessed the efficacy of defined dosages of cannabis-based medicine in 
rheumatoid arthritis pain. Level III studies comprised of three articles that reviewed mixed 
method studies and non-randomized cohort studies. Ark (2016) conducted a literature review of 
level II and level III studies examining cannabis or CBD use in rheumatoid arthritis. Bruni 
(2018) reviewed current clinical trials regarding cannabinoids and their effects on pain and 
inflammation. While, Kraft (2012) explores the clinical data in cannabinoid use for analgesia. 
The level VI evidence found consisted of one review of the historical development of research 
and current evidence on CBD use in numerous diseases including rheumatoid arthritis and other 
inflammatory diseases (Zuardi, 2008). Finally, level VII evidence included two studies of expert 
opinion. Miller et al. (2017) provided a historical review of cannabis and expert opinion on 
current studies assessing the efficacy of cannabinoids in the treatment of joint pain. Booz (2011) 
aimed to review the utility of non-psychotropic CBD in reducing oxidative stress and 
inflammation in diseases such as rheumatoid arthritis and neuropathic pain.  
Populations Studied  
Musculoskeletal pain is one of the most common reasons for primary care visits (Dunphy 
et al., 2015). Rheumatic diseases contribute to many musculoskeletal pain complaints in primary 
care as they are associated with chronic pain and inflammation. Rheumatic disease consists of 
inflammatory and autoimmune conditions that are commonly categorized under the term arthritis 
(Mayo Clinic, 2020). Osteoarthritis and rheumatoid arthritis are examples of common chronic, 
articular types of rheumatic disease. Osteoarthritis involves the degeneration of cartilage within 
joints such as the knee or hip and rheumatoid arthritis affects the synovial membrane within 
joints causing pain, swelling, and stiffness (Mayo Clinic, 2020). Patients with rheumatic disease 
related arthritis suffer daily from pain, immobility, stiffness, physical deformity, and limited 
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range of motion. As many patients with these conditions are seeking relief from the associated 
pain and stiffness, both these conditions are the primary focus of this review. 
Literature Review 
Fitzcharles et al. (2016) conducted a systematic review of the effect of cannabinoids on 
the reduction of pain, sleeping difficulties, fatigue, and quality of life associated with rheumatic 
diseases. Four randomized control studies met inclusion criteria for the systematic review 
conducted by Fitzcharles et al. (2016). Two of those studies focused on fibromyalgia syndrome, 
one study examined chronic spinal pain, and the final study examined rheumatoid arthritis. No 
randomized control trial involving osteoarthritis was found. Within the single study regarding 
rheumatoid arthritis an oral combination spray consisting of CBD 2.5 mg and THC 2.7 mg was 
found to be statistically superior compared to placebo (p =0.02) in reducing morning pain with 
movement and rest, but not overall pain (Fitzcharles et al., 2016). However, frequent side effects 
were reported including dizziness, drowsiness, nausea, and dry mouth along with one serious 
side, a fracture, effect as a result of falling (Fitzcharles et al., 2016). It was unclear, however, if 
any of these were due to CBD or THC. Ultimately, Fitzcharles et al. (2016) concluded that 
currently there is insufficient evidence to recommend any cannabinoid preparations for the 
management of pain associated with rheumatic disease. They also caution that rheumatic disease 
patients requesting CBD or any cannabis treatment should be made aware of the current absence 
of evidence for effect and therefore, these therapies should be reserved for those who have 
exhausted all other pain relief options (Fitzcharles et al., 2016). 
Blake et al. (2006) conducted a randomized, double blind control trial of 58 patients with 
rheumatoid arthritis over the span of five weeks. Using a cannabis-based medicine comprised of 
THC and CBD, the effectiveness in relieving pain with movement, pain at rest, morning 
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stiffness, and impact on sleep quality was measured (Blake et al., 2006). This study observed a 
small but potentially significant analgesic effect with this therapy. Specific to CBD oil, the study 
detected a modest suppression of inflammation activity, as measured by the Disease Activity 
Score, suggesting some anti-inflammatory properties related to CBD oil (Blake et al., 2006). 
These findings suggest some clinical relevance and reinforce the necessity for more detailed 
studies regarding efficacy, dosage, and formulation of CBD products (Blake et al., 2006).    
Using transdermal synthetic CBD oil gel, Hunter et al. (2018) evaluated the safety and 
efficacy of this therapy for the treatment of knee pain due to osteoarthritis in humans. A 
randomized, double-blind placebo controlled multiple dose study of 321 patients was conducted 
over 12 weeks on adults with knee pain due to osteoarthritis (Hunter et al., 2018). Topically, a 
dosage of 250mg twice per day was given versus a placebo (Hunter et al., 2018). Following a 
one-week washout period, implemented to allow cessation of any current analgesics and 
systemic elimination, a one-week baseline period was conducted to capture daily worst pain 
ratings using a 0 to 10 numeric rating scale (Hunter et al., 2018). Weekly thereafter, pain scores 
were then captured using the same pain rating scale and evaluated for changes from baseline 
ratings during the trial period (Hunter et al., 2018). Adverse effects noted during this trial 
included application site dryness and headache (Hunter et al., 2018). After 12 weeks of blinded 
treatment, Hunter et al. (2018) found there were no statistically significant differences between 
the placebo group and CBD gel treatment group on osteoarthritis related pain relief.      
Examining randomized and non-randomized control trials, Ark (2016) evaluated 
literature regarding chronic pain due to rheumatoid disease and the utilization of cannabis or 
CBD. Three human RCTs were reviewed and limited evidence to support CBD for treatment of 
pain caused by inflammatory pathways, autoimmune processes, or neurodegeneration was 
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summarized (Ark, 2016). Conclusions drawn from this mixed review indicated that more human 
studies are needed to determine the efficacy of CBD oil for the treatment of rheumatic disease 
(Ark, 2016).   
An abundant amount of patient testimonies exists regarding the anecdotal therapeutic 
effects of CBD for pain despite the insufficient amounts of rigorous clinical studies conducted 
(Bruni et al., 2018). Thus, Bruni et al. (2018) surveyed current clinical trials regarding 
cannabinoids and their effects on pain and inflammation. Additionally, they analyzed various 
CBD oil administration and delivery forms, such as transdermal and oral-mucosal routes for 
therapeutic benefit (Bruni et al., 2018). Conclusions drawn from this review regarding CBD-
based products for therapeutic pain reduction purposes in forms such as oils, tinctures, and 
vapors, recommend careful consideration when using these products as any potential health risks 
or benefits have not been fully established (Bruni et al., 2018). They caution that while CBD use 
by patients is increasing, additional scientific evaluation of CBD is essential in order to 
determine quality, safety, and efficacy data (Bruni et al., 2018). 
Kraft (2012) acknowledged that there has been a recent resurgence in the medical use of 
the cannabis sativa plant for the purpose of analgesia. Thus, Kraft (2012) analyzed clinical data 
from human trials of multiple forms of cannabinoids, including CBD oil. They concluded that 
due to small sample sizes and short trial durations, findings from these studies were unclear 
regarding the analgesic effects of cannabinoids on rheumatic pain (Kraft, 2012). Some 
supportive evidence found marginal analgesic effects when used as adjuvant therapies but 
recommend that additional well-designed human control studies must be done to confirm these 
findings (Kraft, 2012). 
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Zuardi (2008) acknowledge that CBD oil has a wide range of potential pharmacological 
effects for many conditions including rheumatoid arthritis. The researchers speculate that the 
suppressive effects of CBD oil on immune response and along with the production of pro-
inflammatory mediators suggest some usefulness in rheumatic disease pain (Zuardi, 2008). 
However, a notable finding from this review indicated that the effects of CBD oil were likely 
dose dependent, emphasizing that the lowest most effective dose must be a central factor in 
future CBD research (Zuardi, 2008). Additionally, due to the multiple potential mechanisms of 
action identified, further research is needed to clarify and underline any potential beneficial 
effects of CBD oil (Zuardi, 2008).  
Reducing oxidative stress is often a key target for therapeutic uses of CBD oil. Booz 
(2011) discussed the recent studies suggesting that CBD may have some utility in reducing 
oxidative stress and inflammation within rheumatoid arthritis. They suggest the therapeutic 
action of CBD oil is triggered by the suppression of immune response, specifically by inducing 
apoptosis of lymphocytes (Booz, 2011). However, the mechanism of action surrounding the anti-
inflammatory activities of CBD oil remains to be well-defined (Booz, 2011). Early conjecture 
suggests this may be the result of interruption within intercellular signaling (Booz, 2011). 
Ultimately, given the potentially positive properties such as suspected anti-inflammatory activity, 
immunosuppressive actions, and lack of psychotropic effects of CBD oil, further therapeutic 
studies regarding the utility of this drug are recommended (Booz, 2011).  
Finally, the expert opinion of Miller and Miller (2017) acknowledges that the effects of 
herbal cannabinoids in humans with joint pain needs to be more accurately assessed because 
many patients are choosing to self-medicate with these products. They also recognize that 
patients are reporting benefit from the use of cannabinoids, including CBD, and call for more 
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rigorous clinical evidence to support these claims (Miller & Miller, 2017). Furthermore, they 
point out that it is unclear if CBD alone is helpful in producing analgesic effects as limited 
examination of the effects of individual cannabinoids in patients with rheumatic diseases has 
been conducted (Miller & Miller, 2017). Their findings suggest that due to the lack of rigorous 
clinical studies, there is not enough data to support CBD oil for the treatment of joint pain 
despite the many anecdotal patient statements (Miller & Miller, 2017). 
Quality Indicators 
 Multiple researchers acknowledged the importance of seeking new rheumatic disease 
pain analgesics as traditional analgesics show poor efficacy and leave many patients with 
uncontrolled rheumatic disease pain. The articles reviewed included contribution from many key 
stakeholders including physicians, nurse practitioners, and pharmacists. The hierarchy of 
evidence resulting from this review, however, varied in strength and appropriateness to answer 
the defined clinical question. The use of true experimental research designs to provide the 
highest levels of confidence to answer the clinical question was limited in the current body of 
low-quality evidence. Lower level of confidence studies utilizing non-experimental designs were 
found to be more prevalent within the literature. Additionally, the two experimental studies 
available evaluating the defined clinical question varied largely in sample size and in their 
measurement of treatment effects. At present, there are also many confounding variables 
identified within the research including mixed patient populations, different cannabinoid 
preparations, various formulations, and wide dosing ranges (Bruni et al., 2018). On the other 
hand, despite the multiple research designs used, recommendations regarding the use of CBD for 
rheumatic disease pain were all together consistent.  
Gaps in Literature 
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 Major gaps in literature stem from the absolute lack of research regarding CBD in 
general. At present, very few human studies provide tangible evidence concerning the 
appropriate dose, route, frequency, safety, and efficacy of CBD. Furthermore, available human 
research studies related solely to CBD oil use for rheumatic disease pain are even more meagre, 
as most research has been conducted for its use in conditions such as cancer related pain and 
epilepsy. Thus, rigorous human clinical control trials aimed to determine both long and short-
term effects, lowest efficacious dose, most effective route, safety, and risk of adverse effects 
must be conducted in order to strengthen the evidence regarding the use of CBD oil for 
rheumatic disease pain. 
 As many studies within this review contained various modes of administration, the most 
effective route remains unknown. Additionally, this gap significantly weakens the pool of current 
research as parallels are unable to be made amongst data. In addition, this variance further 
impedes any supportive evidence validating the lowest efficacious dose with the fewest side 
effects. Thus, it remains that additional rigorous evidence is needed to determine the most 
efficacious, safe, and efficient mode of administering CBD. 
 Best practices and recommendations found within this review were not promising 
regarding CBD oil use for rheumatic disease pain. Most literature findings resulted in the call for 
more rigorous studies to be conducted before any further practice related guidance could be 
drawn. In fact, while many studies emphasized the importance of seeking new rheumatic pain 
management strategies, none could conclude that CBD oil use for the treatment of rheumatic 
disease pain was better than current pain management strategies. Ultimately, the level of 
evidence supporting the use of CBD oil in rheumatic disease pain is minimal and therefore, 




 Cannabinoids have long been used for recreational and medicinal purposes. More 
recently cannabinoid products have been used across the world for their therapeutic properties in 
chronic pain relief, epilepsy, and even addiction. Due to its low THC concentration, the 
cannabinoid CBD oil has become popular as an over the counter medication for rheumatic 
disease pain relief. Notably, regulation of these products is limited, allowing for inconsistent 
labeling of CBD oil sold over the counter. However, with the passage of the 2014 Agricultural 
Act, the growth of hemp or Cannabis sativa L. with a THC content of no more than 0.3% was 
legalized for the purposes of research in the United States and CBD was removed from the 
controlled substances act (VanDolah et al., 2019). This has led to state law changes regarding its 
sale and new labeling requirements.  
 Many uncertainties remain regarding the roll of cannabinoids for the management of 
rheumatic pain. Despite the paucity of evidence regarding their safety and efficacy, patients 
frequently use these products for pain relief for their rheumatic disease. In summary of the 
evidence identified for this review, a modest suppression of inflammation activity suggests anti-
inflammatory and immunomodulating properties of CBD oil and potentially indicates some 
clinical relevance (Blake et al., 2006). However, direct correlation to exact mechanisms are not 
able to be concluded and therefore only reinforce the need for more detailed studies regarding 
efficacy, lowest effective dose, and most appropriate formulation of CBD products (Blake et al., 
2006). Other supportive evidence found indicated marginal analgesic effects when used as 
adjuvant therapy and recommended that additional well-designed human control studies must be 
done to confirm these findings (Kraft, 2012). On the other hand, some studies found side effects 
including dizziness, drowsiness, nausea, and dry mouth, yet it was unclear whether these were 
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due to CBD or another ingredient within the product. Additionally, multiple authors pointed out 
that any potential health risks or benefits have not been fully established and further research is 
needed to explore these areas. A common theme found within all nine articles reviewed indicated 
that given the potentially positive properties including anti-inflammatory activity, 
immunosuppressive actions, and lack of psychotropic effects, further therapeutic studies 
regarding the utility of CBD oil are warranted. While many studies emphasized the importance 
of seeking new rheumatic pain management strategies, none could conclude that CBD oil use for 
the treatment of rheumatic disease pain was better than current pain management therapies. 
 To date, the available evidence related to the clinical question is minimal. There are very 
few rigorous studies conducted that solely assess the clinical effectiveness of CBD oil for 
rheumatic disease related pain. Far more literature containing anecdotal evidence or expert 
opinion is available at this time. As safer and more effective alternative therapies for the relief of 
rheumatic disease is sought, it is imperative we do our due diligence and scientifically study the 
potential CBD oil may provide in pain relief before we advise its routine use. Anecdotal 
statements cannot be allowed to supersede evidenced based, high-quality research regarding 
CBD nor risk patient harm by recommending its use without scientific proof of its safety. Many 
studies within this review brought forward concerns for unknown harms or side effects if careful 
examination of CBD oil use for rheumatic disease pain if left undone. Therefore, it is important 
to take the time to formulate multiple thorough experimental studies that assess the safety and 
efficacy of CBD oil in rheumatic disease pain. Imperatively, these studies must align and analyze 
appropriate route, strength, short and long-term effects, side effects, risk for addiction, efficacy 
and safety before any recommendations for use can be made.  
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 Finally, it is imperative that health care providers have a clear understanding of the 
efficacy of CBD oil in relieving rheumatic disease pain as patients may seek their counsel on the 
use of these products. Many studies within this review acknowledged that due to various modes 
of administration, the most effective route and lowest effective dose of CBD remains unknown. 
As a result, the research found to date is inconclusive regarding the efficacy of CBD oil for 
rheumatic disease pain relief. Thus, it remains that additional rigorous evidence is needed to 
determine the most efficacious, safe, and efficient mode of administering CBD. Due to the lack 
of congruent evidence found in this review, it is surmised that health care providers should not 
advocate for routine use of CBD oil until further rigorous studies are conducted. 
Implications for Future 
 At present, due to the lack of available evidence-based literature needed to answer the 
identified clinical question, few proposals for CBD as a future therapy in rheumatic disease pain 
are suggested. The following areas have been identified for discussion of necessary future 
recommendations and include clinical practice management, patient and provider education, key 
research needs, and requests for healthcare policy.     
Clinical Practice Recommendations  
Maintaining clinical curiosity and a healthy respect for skepticism is key to the 
exploration of new pain management options within rheumatic disease. At present, current 
traditional analgesic management is inadequate, leaving many patients seeking new therapies for 
pain relief. Yet, due to the low quantity and quality of available evidence on the efficacy, 
tolerability, and safety of CBD in rheumatic disease pain relief, recommending CBD oil for 
routine clinical is not advised (Fitzcharles, 2016). Therefore, CBD oil should only be cautiously 
considered as an adjunctive, complementary therapy in the management of rheumatic disease 
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pain (Sarzi-Puttini et al., 2019). Until known safety, efficacy, side effects, and confidence in 
accurate over the counter drug labeling is observed, providers should prudently address patient 
questions regarding routine CBD use for rheumatic disease pain.     
Recommendations for Research  
 CBD is a non-intoxicating and potentially useful substance with increasing patient 
interest (VanDolah, 2019). Despite non-FDA approval for therapeutic use, patients continue to 
use CBD oil regardless of potential safety concerns, side effects, or lack of evidence supporting 
its therapeutic benefit (VanDolah, 2019). This considerably risky choice, especially in patients 
with rheumatic disease, stems from the poor pain management therapies currently available and a 
desperate need for potentially better pain relief alternatives such as CBD oil. Therefore, more 
research is obligatory to better understand its potential for efficacy, safety, and to define its role 
in the management of rheumatic disease pain (Fitzcharles, 2016). It is also essential that future 
research studies must astutely examine dosages and concentration as some research suggests 
these are pivotal factors needed to determine efficacy and safety (Zuardi, 2008). Without a 
doubt, future rigorous double-blind randomized placebo control trials aimed at determining the 
short- and long-term efficacy and safety of CBD oil are desperately needed as patients are using 
CBD products despite the lack of evidence. 
Education Recommendations  
 There are more than one hundred known cannabinoids derived from the cannabis plant 
but the most commonly known are THC and CBD. Due to popularity, the sale and use of these 
products has grown significantly in recent years. Concerningly, this rapid increase has left many 
patients and providers unclear about the ingredients in the numerous different cannabinoid 
products available both over the counter and by prescription. As cannabinoid compounds vary in 
their active ingredients and systemic effects, clear understanding of the commonly used 
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cannabinoids is crucial for patients and providers. Therefore, education must be intended to 
inform patients and providers about the different cannabinoid compounds sold, their effects, and 
their respective the terminology. Furthermore, this education is essential for healthcare providers 
in order to have a strong familiarity with each product and accurately provide patients with 
information about cannabinoids when approached. 
 The regulation of cannabinoid products varies significantly at the federal and state level, 
leading to ongoing confusion related to CBD oil legality. Furthermore, recent changes regarding 
the growth of hemp plants for commercial cultivation leaves many unclear on whether CBD oil 
from hemp is legal to be sold and consumed. Thus, dissemination of the current regulations of 
these products should be done in order to provide patients and providers with clarity regarding 
the legality of CBD oil in their state. 
 Oftentimes providers are questioned by patients about CBD oil use for pain relief. 
However, because little evidence is known about the therapeutic benefit of CBD, doubt in its 
effectiveness is presented. This cannabinoid skepticism, while fitting given the lack of evidence, 
must be confronted in order to develop a greater understanding of the therapeutic role of CBD oil 
(Sarzi-Puttini et al., 2019). It is important that providers to maintain mental flexibility and 
openness to seeking safer and more effective alternatives for rheumatic disease pain as 
conventional therapies are failing to provide adequate relief (Sarzi-Puttini et al., 2019). To 
support this, providers must be educated on the current body of evidence, its recommendations, 
and advocate for further rigorous research studies to be conducted in order to better guide 
patients.  
 Ultimately, despite the lack of high-quality evidence, patients continue to use CBD oil for 
rheumatic disease pain relief. With an open-minded approach, providers must use caution when 
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recommending CBD oil to patients until additional studies have been conducted. To best guide 
patients understanding, informed providers should share the findings from the current body of 
evidence regarding the efficacy and safety of these products with patients. In addition, a 
collaborative approach should be maintained if patients choose to use CBD oil in order to 
maintain patient trust and safeguard quality of life.  
Recommendations for Policy  
 Presently, no guidelines have been endorsed by a national guideline clearinghouse or 
rheumatology association recommending CBD oil for the management of rheumatic disease pain 
(Sarzi-Puttini et al., 2019). Furthermore, because of the lack of evidence some rheumatology 
associations recommend against using cannabinoids for the treatment of pain associated with 
rheumatological conditions including osteoarthritis (Sarzi-Puttini et al., 2019). At present time, 
recommendations for policy changes cannot be made due to the lack of high-quality evidence 
supporting CBD oil’s efficacy and safety for the treatment of rheumatic disease pain. Any 
recommendations for future policy changes must be made based on rigorous evidence-based 
studies as anecdotal testimony and expert advice is not enough to protect patients from any 
unknown harmful effects.  
Conclusion 
 The paucity of supporting evidence that exists leaves many questions unanswered 
regarding CBD oil’s place in the clinical management of rheumatic disease pain. It is not a secret 
that the current analgesic drugs are suboptimal at best for the management of rheumatic disease 
pain (Sarzi-Puttini et al., 2019). Furthermore, some have even led to catastrophic health related 
effects such as addiction and even death and have done little to improve the quality of life for 
patients with rheumatic disease (Sarzi-Puttini et al., 2019). Taking this into consideration, safer 
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alternative therapies for pain management are desperately needed as rheumatic diseases are 
lifelong and require clinically proven safe analgesic drugs to safeguard quality of life (Sarzi-
Puttini et al., 2019). Thus, it is imperative to maintain openness to potentially safer alternatives 
to rheumatic disease pain such as CBD oil. Now more than ever patients are seeking alternative 
therapies for rheumatic disease pain, the necessity for rigorous clinical studies designed to 
determine whether CBD oil is an effective and safe alternative has never been more imperative. 
In conclusion, providers alike should take a careful approach regarding the use of CBD oil for 
patients with rheumatic disease pain by limiting advocacy to those who have exhausted all other 
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